Science
Partnerships
About
News & Media
Careers
Twitter
LinkedIn
hello@kernalbio.com
News & Media
10.31
.2023
Kernal Biologics to Present at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Press release
07.20
.2023
Kernal Biologics to Present at 3rd Annual mRNA-Based Therapeutics Summit
Press release
05.09
.2023
Kernal Biologics to Present at Locust Walk RNA Innovation Conference
PRN
01.09
.2023
Kernal Biologics to Present at Biotech Showcase
Press release
11.16
.2022
Kernal Biologics' mRNA 2.0 is featured on STAT
statnews
11.09
.2022
Kernal Biologics Announces Presentations at The International mRNA Health Conference
Press Release
07.07
.2022
Pushing mRNA therapeutics for cancer, Cambridge startup nabs Series A to explore next-gen approach
Endpoints News
07.07
.2022
Amgen-backed Kernal Biologics pops off with $25M for mRNA platform
Fierce Biotech
07.07
.2022
Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology
PRN
12.05
.2021
The Vast Promise of mRNA Technology
Wall Street Journal
11.09
.2021
Kernal Biologics Presenting Results at the 9th Annual mRNA Health Conference
Globe Newswire
09.02
.2021
Startups set off new wave of mRNA therapeutics
Nature Biotech
07.22
.2021
Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product
12.22
.2020
Targeted delivery, oral vaccines and mRNA 2.0: The next generation of drugs and prophylactics in the fight against COVID-19
FiercePharma
10.10
.2020
You've met Moderna, BioNTech and CureVac. Now meet Kernal Bio, the startup working on mRNA 2.0.
FierceBiotech
10.02
.2020
Kernal mRNAs are heading to space!
CNN
02.28
.2019
Kernal is accepted to MassBio's MassConnect Program
12.18
.2018
Kernal Biologics wins Amgen's coveted Golden Ticket award for the second year in a row
10.18
.2018
Kernal Biologics receives Technology in Space Award from CASIS & Boeing through MassChallenge
09.03
.2018
Can mRNA disrupt the drug industry?
C&EN